ClinicalTrials.gg
RecruitingNCT06991855Updated Jun 22, 2025

Effects of Nutritional Supplementation of Leucine and Polyunsaturated Fatty Acids on Muscle Health in the Elderly

An interventional study of Animal-Based Oil Group and Plant-Based Oil Group in Sarcopenia and Sarcopenia in Elderly, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
50 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Sarcopenia by Chang Gung Memorial Hospital — 8 open to participants now, 8 under way, none of them phase 3. Sarcopenia · Chang Gung Memorial Hospital.

Planned enrollment
6th of 11
90 · median 90
Started
2025
with 1 other
No phase
11 of 14
7 open now
Registered
11th of 14
by date

Among the 14 studies in Sarcopenia by Chang Gung Memorial Hospital, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 11th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

8 of the 14 studies in Sarcopenia by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 50 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sarcopenia by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

Population aging has become a significant global concern, and Taiwan is set to officially enter the "super-aged society" in 2025. As individuals age, various physiological functions gradually decline, including a reduction in muscle mass, which is a key aspect of the aging process.

This interventional study aims to investigate the effects of leucine-rich protein combined with polyunsaturated fatty acid supplementation on middle-aged and elderly individuals (aged 50 and above) who are at high risk for sarcopenia.

03

Conditions studied

  • Sarcopenia
  • Sarcopenia in Elderly

Browse trials for

04

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years
  • ASMI \< 7 kg/m2 in men
  • ASMI \< 5.7 kg/m2 in women
  • Grip strength \< 28 kg in men
  • Grip strength \< 18 kg in women
  • Walk speed \< 1 m/s

Exclusion criteria

Exclusion Criteria:

  • People who are allergic to supplements
  • cancer
  • heart failure
  • kidney disease
  • disease
  • neurodegenerative disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Animal-Based Oil Group

    Participants in this group will supplement with animal-based poly-unsaturated oil. The supplementation will be maintained for 12 weeks.

    Dietary Supplement: Animal-Based Oil Group

  • Experimental
    Plant-Based Oil Group

    Participants in this group will supplement with plant-based poly-unsaturated oil. The supplementation will be maintained for 12 weeks.

    Dietary Supplement: Plant-Based Oil Group

Interventions

  • Dietary supplementAnimal-Based Oil Group

    Participants in animal-based oil group will follow a diet in which the primary fat source is animal-based oil. The diet will supplement for 12 weeks.

  • Dietary supplementPlant-Based Oil Group

    Participants in plant-based oil group will follow a diet in which the primary fat source is plant-based oil. The diet will supplement for 12 weeks.

06

What researchers measure

Primary outcomes

  1. muscle mass

    Utilize Bioelectrical Impedance Analysis (BIA) to measure the Appendicular Skeletal Muscle Mass Index Level (ASMI) (kg/m\^2)

    Time frame: baseline, 12 weeks

  2. muscle function

    utilize handgrip dynamometer to measure the hand grip strength (kg).

    Time frame: baseline, 12 weeks

  3. physical function

    To assess the participant's walking speed over a 4-meter distance.

    Time frame: baseline, 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Apr 2026, 9 months later.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 9 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
May 28, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Apr 10, 2026
CompletionEst.
Apr 17, 2026
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991855
Collaborators
Chang Gung University
Responsible party
JI-TSENG FANG (Professor, Chang Gung Memorial Hospital) — Principal investigator
First posted
May 28, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Apr 10, 2026 (estimated)
Completion
Apr 17, 2026 (estimated)
Last update
Jun 22, 2025

Study contacts

Hsiang-Yu Tang, Ph.D.
Contact
tangshyu@cgu.edu.tw
+886-3-2118800 ext. 3650
Yi Tsang Chen, Master of Science
Contact
ytchen@fpg.com.tw
+886-2-2712-2211 ext. 7358

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion